Phibro Animal Health Corporation— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$374M
↑+20.9% +$65Mvs FY2024 (Q4)
Gross Profit
$133M
↑+30.2% +$31Mvs FY2024 (Q4)
Operating Income
$50M
↑+97.1% +$25Mvs FY2024 (Q4)
Net Income
$27M
↑+762.1% +$24Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $374M | $309M |
| COGS | $241M | $207M |
| Gross Profit | $133M | $102M |
| R&D | $0 | $0 |
| SG&A | $82M | $76M |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $50M | $26M |
| Interest Exp. | $14M | $10M |
| Other Non-Op | $0 | $11M |
| Pretax Income | $36M | $5M |
| Tax | $9M | $2M |
| Net Income | $27M | $3M |
QuarterCharts · SEC EDGAR data · PAHC · Comparing FY2025 (Q4) vs FY2024 (Q4)